US biotech bluebird bio (Nasdaq: BLUE) looked set to open Thursday’s trading almost 14% lower after announcing an update on its US filing of LentiGlobin for sickle cell disease (bb1111).
The company confirmed its general agreement with the US Food and Drug Administration (FDA) that the clinical data package required to support the Biologics License Application (BLA) will be based on data from a portion of patients in the HGB-206 study Group C that have already been treated.
A path to transition to commercial manufacturing using an analytical comparability strategy, including suspension-based lentiviral vector, has also been agreed with the FDA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze